Early neoplastic progression is complement independent.

Infiltration of leukocytes into premalignant tissue is a common feature of many epithelial neoplasms and is thought to contribute to cancer development. However, the molecular and cellular regulatory mechanisms underlying activation of innate host responses to enhanced neoplastic cell proliferation are largely unknown. Considering the importance of the complement system in regulating inflammation during acute pathologic tissue remodeling, we examined the functional significance of complement component 3 (C3) as a regulator of inflammatory cell infiltration and activation during malignant progression by using a transgenic mouse model of multistage epithelial carcinogenesis, e.g., HPV16 mice. Whereas abundant deposition of C3 is a characteristic feature of premalignant hyperplasias and dysplasias coincident with leukocyte infiltration in neoplastic tissue, genetic elimination of C3 neither affects inflammatory cell recruitment toward neoplastic skin nor impacts responding pathways downstream of inflammatory cell activation, e.g., keratinocyte hyperproliferation or angiogenesis. Taken together, these data suggest that complement-independent pathways are critical for leukocyte recruitment into neoplastic tissue and leukocyte-mediated potentiation of tumorigenesis.

[1]  J. Hodgson,et al.  TIMP-1 Alters Susceptibility to Carcinogenesis , 2004, Cancer Research.

[2]  P. Askenase,et al.  B-1 B Cells Mediate Required Early T Cell Recruitment to Elicit Protein-Induced Delayed-Type Hypersensitivity 1 , 2003, The Journal of Immunology.

[3]  R. López‐Ridaura,et al.  Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis , 2003, BMC Cancer.

[4]  Alan D. Lopez,et al.  Correction: Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000 , 2003, BMC Cancer.

[5]  D. Hanahan,et al.  Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.

[6]  V. Secor,et al.  Cutting Edge: Both Activating and Inhibitory Fc Receptors Expressed on Mast Cells Regulate Experimental Allergic Encephalomyelitis Disease Severity 1 , 2003, The Journal of Immunology.

[7]  L. Coussens,et al.  Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. , 2002, Differentiation; research in biological diversity.

[8]  Toshiaki Kawakami,et al.  Regulation of mast-cell and basophil function and survival by IgE , 2002, Nature Reviews Immunology.

[9]  Ruoyan Chen,et al.  Macrophages, But Not T and B Lymphocytes, Are Critical for Subepidermal Blister Formation in Experimental Bullous Pemphigoid: Macrophage-Mediated Neutrophil Infiltration Depends on Mast Cell Activation1 , 2002, The Journal of Immunology.

[10]  M. Wills-Karp,et al.  Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. , 2002, American journal of respiratory cell and molecular biology.

[11]  H. Jick,et al.  Association Between Acetaminophen or Nonsteroidal Antiinflammatory Drugs and Risk of Developing Ovarian, Breast, or Colon Cancer , 2002, Pharmacotherapy.

[12]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[13]  Y. Okayama,et al.  IgG‐dependent activation of human mast cells following up‐regulation of FcγRI by IFN‐γ  , 2001 .

[14]  M. Cotterchio,et al.  Nonsteroidal anti-inflammatory drug use and breast cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  Rick A. Wetsel,et al.  Cutting Edge: The Absence of C3 Demonstrates a Role for Complement in Th2 Effector Functions in a Murine Model of Pulmonary Allergy1 , 2001, The Journal of Immunology.

[16]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[17]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[18]  M. Walport Complement. First of two parts. , 2001, The New England journal of medicine.

[19]  L. Hansson,et al.  Aspirin and risk for gastric cancer: a population-based case–control study in Sweden , 2001, British Journal of Cancer.

[20]  John D Lambris,et al.  Structure and biology of complement protein C3, a connecting link between innate and acquired immunity , 2001, Immunological reviews.

[21]  L. G. García Rodríguez,et al.  Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs , 2001, Epidemiology.

[22]  R. Ames,et al.  Cutting Edge: Guinea Pigs with a Natural C3a-Receptor Defect Exhibit Decreased Bronchoconstriction in Allergic Airway Disease: Evidence for an Involvement of the C3a Anaphylatoxin in the Pathogenesis of Asthma1 , 2000, The Journal of Immunology.

[23]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[24]  H. Kawamoto,et al.  Correlation between Deposition of Immuno‐Components and Infiltration Pattern of Polymorphonuclear Leukocytes in the Lesions of Chronic Urticaria , 2000, The Journal of dermatology.

[25]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[26]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[27]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[28]  P. Wolters,et al.  Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. , 1999, Journal of immunology.

[29]  D. Broide,et al.  A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. , 1999, Journal of immunology.

[30]  J. Guitart,et al.  Preferential activation of the complement system in the lower epidermis of patients with pemphigus vulgaris , 1998, The British journal of dermatology.

[31]  H. Dvorak,et al.  Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression , 1998, The Journal of experimental medicine.

[32]  P. Welker,et al.  Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. , 1998, Molecular biology of the cell.

[33]  A. Andoh,et al.  A blockade of complement activation prevents rapid intestinal ischaemia‐reperfusion injury by modulating mucosal mast cell degranulation in rats , 1998, Clinical and experimental immunology.

[34]  S. Galli,et al.  Impaired mast cell-dependent natural immunity in complement C3-deficient mice , 1997, Nature.

[35]  T. Zuberbier,et al.  C3a and C5a stimulate chemotaxis of human mast cells. , 1997, Blood.

[36]  T. Halstensen,et al.  Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. , 1997, Gut.

[37]  D. Hanahan,et al.  Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.

[38]  J. Ravetch,et al.  A dominant role for mast cell Fc receptors in the Arthus reaction. , 1996, Immunity.

[39]  G. Nilsson,et al.  C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. , 1996, Journal of immunology.

[40]  P. Butko,et al.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Jakschik,et al.  The Role of Mast Cells and Their Mediators in IgG-Antigen Complex-Mediated Inflammation. , 1995, American journal of therapeutics.

[42]  P. Norman Immunobiology: The immune system in health and disease , 1995 .

[43]  J. Ravetch,et al.  Cytotoxic antibodies trigger inflammation through Fc receptors. , 1995, Immunity.

[44]  G. Till,et al.  The role of complement in experimental bullous pemphigoid. , 1995, The Journal of clinical investigation.

[45]  J. Ravetch,et al.  Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. , 1994, Science.

[46]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[47]  D. Friend,et al.  Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Troy,et al.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. , 1993, The Journal of clinical investigation.

[49]  S. Weitzman,et al.  Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. , 1990, Blood.

[50]  T. Halstensen,et al.  Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. , 1990, Gastroenterology.

[51]  William Arbuthnot Sir Lane,et al.  Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[52]  H. Müller-Eberhard,et al.  Release of histamine from rat mast cells by the complement peptides C3a and C5a. , 1975, Immunology.

[53]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[54]  Y. Fujiyama,et al.  Role of Complement Activation and Mast Cell Degranulation in the Pathogenesis of Rapid Intestinal Ischemia/Reperfusion Injury in Rats , 2001, Digestion.

[55]  D. Metcalfe,et al.  IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. , 2001, European journal of immunology.

[56]  B. Gold,et al.  The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. , 2000, Annual review of microbiology.

[57]  J A Hanley,et al.  Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .